Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Verastem Oncology (VSTM) has announced new equity compensation grants to fifteen employees. The company granted stock options to purchase 164,500 shares of common stock to fourteen new employees at an exercise price of $5.82 per share, matching the closing price on April 1, 2025. Additionally, one new employee received 83,333 restricted stock units.
The grants were made under Nasdaq's inducement grant exception (Rule 5635(c)(4)). The stock options and 50,000 RSUs will vest 25% after one year, with remaining shares vesting quarterly over three years. The additional 33,333 RSUs will vest based on sales milestone achievements. All vestings are contingent on continued employment with Verastem Oncology.
Verastem Oncology (VSTM) ha annunciato nuovi premi in azioni per quindici dipendenti. L'azienda ha concesso opzioni su azioni per acquistare 164.500 azioni ordinarie a quattordici nuovi dipendenti a un prezzo di esercizio di 5,82 $ per azione, corrispondente al prezzo di chiusura del 1 aprile 2025. Inoltre, un nuovo dipendente ha ricevuto 83.333 unità di azioni vincolate.
I premi sono stati concessi ai sensi dell'eccezione per le concessioni di indennità di Nasdaq (Regola 5635(c)(4)). Le opzioni su azioni e 50.000 RSU matureranno del 25% dopo un anno, con le azioni rimanenti che matureranno trimestralmente per tre anni. Le ulteriori 33.333 RSU matureranno in base al raggiungimento di traguardi di vendita. Tutte le maturazioni sono subordinate al mantenimento dell'impiego presso Verastem Oncology.
Verastem Oncology (VSTM) ha anunciado nuevas concesiones de compensación en acciones para quince empleados. La compañía otorgó opciones sobre acciones para comprar 164,500 acciones ordinarias a catorce nuevos empleados a un precio de ejercicio de $5.82 por acción, coincidiendo con el precio de cierre del 1 de abril de 2025. Además, un nuevo empleado recibió 83,333 unidades de acciones restringidas.
Las concesiones se realizaron bajo la excepción de concesión de inducción de Nasdaq (Regla 5635(c)(4)). Las opciones sobre acciones y 50,000 RSUs se consolidarán en un 25% después de un año, con las acciones restantes consolidándose trimestralmente durante tres años. Las 33,333 RSUs adicionales se consolidarán en función del logro de hitos de ventas. Todas las consolidaciones están condicionadas a la continuidad del empleo en Verastem Oncology.
Verastem Oncology (VSTM)는 15명의 직원에게 새로운 주식 보상 지급을 발표했습니다. 이 회사는 14명의 신규 직원에게 164,500주의 보통주를 구매할 수 있는 주식 옵션을 $5.82의 행사 가격으로 부여했으며, 이는 2025년 4월 1일의 종가와 일치합니다. 또한, 한 명의 신규 직원은 83,333 제한 주식 단위를 받았습니다.
이 지급은 Nasdaq의 유도 지급 예외(규칙 5635(c)(4))에 따라 이루어졌습니다. 주식 옵션과 50,000 RSU는 1년 후 25%가 발생하며, 나머지 주식은 3년 동안 분기별로 발생합니다. 추가로 33,333 RSU는 판매 이정표 달성에 따라 발생합니다. 모든 발생은 Verastem Oncology에서의 지속적인 고용에 따라 달라집니다.
Verastem Oncology (VSTM) a annoncé de nouvelles attributions de compensation en actions pour quinze employés. La société a accordé des options d'achat d'actions pour acquérir 164 500 actions ordinaires à quatorze nouveaux employés à un prix d'exercice de 5,82 $ par action, correspondant au prix de clôture du 1er avril 2025. De plus, un nouvel employé a reçu 83 333 unités d'actions restreintes.
Les attributions ont été effectuées dans le cadre de l'exception de concession d'incitation de Nasdaq (Règle 5635(c)(4)). Les options d'achat d'actions et 50 000 RSU acquériront 25 % après un an, les actions restantes s'acquérant trimestriellement sur trois ans. Les 33 333 RSU supplémentaires s'acquerront en fonction de l'atteinte de jalons de vente. Toutes les acquisitions sont conditionnées à la poursuite de l'emploi chez Verastem Oncology.
Verastem Oncology (VSTM) hat neue Aktienvergütungen für fünfzehn Mitarbeiter angekündigt. Das Unternehmen hat vierzehn neuen Mitarbeitern Aktienoptionen zum Kauf von 164.500 Aktien zu einem Ausübungspreis von 5,82 $ pro Aktie gewährt, was dem Schlusskurs vom 1. April 2025 entspricht. Darüber hinaus erhielt ein neuer Mitarbeiter 83.333 eingeschränkte Aktieneinheiten.
Die Vergaben wurden gemäß der Ausnahme für Anreizvergaben von Nasdaq (Regel 5635(c)(4)) vorgenommen. Die Aktienoptionen und 50.000 RSUs werden nach einem Jahr zu 25% fällig, während die verbleibenden Aktien vierteljährlich über drei Jahre fällig werden. Die zusätzlichen 33.333 RSUs werden basierend auf dem Erreichen von Verkaufsmeilensteinen fällig. Alle Fälligkeiten sind an die Fortsetzung der Anstellung bei Verastem Oncology gebunden.
- Performance-based incentives through milestone-linked RSUs indicate focus on sales growth
- Employee retention strategy through long-term vesting schedule
- Potential shareholder dilution from 247,833 new shares
About Verastem Oncology
Verastem Oncology (Nasdaq: VSTM) is a late-stage development biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition, FAK inhibition and KRAS G12D inhibition. For more information, please visit www.verastem.com and follow us on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250407925188/en/
For Investor and Media Inquiries:
Julissa Viana
Vice President, Corporate Communications
Investor Relations and Patient Advocacy
investors@verastem.com or
media@verastem.com
Source: Verastem Oncology
FAQ
What is the exercise price for VSTM's newly granted stock options in April 2025?
How many shares are covered by VSTM's latest employee stock option grants?
What is the vesting schedule for VSTM's new employee stock options?
How many restricted stock units (RSUs) did VSTM grant in its latest announcement?
